Russia claims 91.4% efficacy rate in new Covid-19 vaccine data
The results are crucial for India, where the vaccine is being tested on humans in mid- to late-stage trials by Hyderabad-based Dr Reddy’s Laboratories. Updated: December 14, 2020 7:52:38 pm
Sputnik V vaccine has been developed by the Gamaleya National Research Center of Epidemiology and Microbiology and Russian Direct Investment Fund (RDIF). (File)
Russian
coronavirus vaccine developers published fresh results from their trial of the Sputnik V vaccine on Monday based on new data, and said the shot had again been found to be 91.4% effective in providing protection from Covid-19. The results are
BENGALURU: Overall global orders to secure vaccines shrunk 19.2 million doses to touch 7.1 billion as of December 11, compared to 7.12 billion as of November 30. India, which had deals for 1.6 billion doses by the end of last month has 1.5 billion as per data from Duke University’s Launch & Scale Speedometer, which is tracking global vaccine deals daily.
Analysis of contracts countries are signing with vaccine makers for advance booking of candidates shows that the deals are still fluid, changing in a matter of days with some companies gaining and some losing orders given that most candidates are still in trial stage.
Among vaccine makers, orders with Oxford-Astrazeneca shrunk more than 30 million doses to touch 2.47 billion, compared to 2.5 billion as of November 30, while Pfizer-BioNTech vaccine, the only to be administered to people so far, saw additional orders for 73.2 million to touch 719 million as of December 11. Moderna saw fresh deals for 29 million doses.
Aditi Tandon
New Delhi, December 10
India is eyeing affordable Covid-19 vaccines with eight under production in the country. Besides two leading vaccine candidates Serum Institute’s Covishield and Bharat Biotech-ICMR’s Covaxin, six more vaccines are in advanced stages of development.
Cadila Healthcare Ahmedabad’s ZyCoV-D, an indigenous DNA vaccine, is currently in phase 2 trials, while Sputnik-V, the Russian candidate which has collaborated with Hyderabad-based Dr Reddy’s for India trials, has completed phase 2 trials and will start late stage phase 3 tests next week.
New cases stay under 40K
New cases remained below 40,000 for the 11th day in a row. Daily deaths remained below 500 for the fifth day. Haryana (26) and Punjab (16) are among the 10 states with 78% of the 412 deaths that have occurred in a day.